ReNeuron : Preliminary results presentation for the year ended 31 March 2021

2021 PRELIMINARY RESULTS PRESENTATION

08 July 2021

Olav Hellebø - Chief Executive Officer

Dr Rick Beckman - Chief Medical Officer

John Hawkins - Financial Controller

DISCLAIMER

This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed to any other person or published, in wholeorin part,forany purpose. Subject to certain exceptions, this Presentation is not for distribution in the United States, Australia, Canada or Japan or any other jurisdiction whereits distributionmayconstitute a violation of the laws of such jurisdiction.

The information contained in this document ("Presentation") has been prepared by ReNeuron Group plc (the "Company") and neither this Presentation, nor theinformation contained in it should be considered a recommendation by the Company or any of its shareholders, directors, officers, agents, employees or advisers in relation to any purchase of the Company's securities, including any purchase of or subscription for any shares (or securities convertible into shares) in the capital of the Company. This Presentation hasnot been fully verified and is subject to material updating, revision and further amendment. Any person who receives this Presentation should not rely or act upon it. This Presentation should not be re-distributed,re-published, reproduced or disclosed by recipients, in whole or in part.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements and past performance is no guarantee of future performance. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, revenue generation, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000.

In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent. This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. In particular, this Presentation is for information purposes and does not constitute an offer or invitation to subscribe for or purchase any securities in the United States. The securities of the Company have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in accordance with any applicable state securities laws. There will be no public offering of the securities of the Company in the United States.

By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

© ReNeuron Group plc 2021 All rights reserved

2

RENEURON: HIGHLIGHTS

Leading clinical stage cell therapy company with presence in the UK and US

Proprietary allogeneic retinal and neural stem cell therapy platforms

Lead programme an Orphan Drug treatment with Fast Track Designation targeting retinitis pigmentosa (RP) - positive early Phase 2a clinical data with study ongoing

Planning to commence pivotal RP clinical trial in H2 2022, with data targeted for 2024, ahead of market approval application

Proprietary exosome programme - collaborations ongoing with pharma & biotech, with further collaborations anticipated

Well-funded following recent £17.5m capital raise. Extended RP Phase 2a clinical data readouts and exosome pre-clinicalproof-of-concept data expected Q4 2021

© ReNeuron Group plc 2021 All rights reserved

3

PROPRIETARY PLATFORM TECHNOLOGIES

hRPC

Exosome Platform

iPSC Platform		CTX Cells

Human Retinal Progenitor Stem Cells with sub-retinal delivery enabling engraftment

Cryopreserved formulation allows global ship-

and-store

Positive early Phase 2a data in ongoing

retinitis pigmentosa study

Partnered with Fosun Pharma for China

High-yielding neural

stem cell derived exosomes

Proven ability to load exosomes with siRNA,

miRNA and proteins

Favourable distribution of exosomes across

the Blood Brain Barrier

Potential as drug load/delivery vehicle

and as a therapeutic. Pharma

collaborations ongoing

CTX-based induced

pluripotent

stem cell platform

Neural stem cells

engineered into other

forms of stem cells while

preserving the

immortalisation

Potential to create

allogeneic CAR-T cell

therapies and

pancreatic islet cells

Immortalised neural

progenitor

stem cell line

Positive clinical data in

stroke disability. Potential in Huntington's disease, TBI and other indications

Out-licensing strategy

Partnered with Fosun

Pharma for China

© ReNeuron Group plc 2021 All rights reserved

4

INTERNAL RESEARCH AND DEVELOPMENT PIPELINE

Programme

Human Retinal Progenitor Cells

Exosome platform

iPSC platform

CTX cell line

Indication	Pre-clinical	Phase 1	Phase 2	Next Milestones
				• Further data read-outs from
Retinitis				expanded Phase 2a study expected
			Q4 2021
Pigmentosa
			• Pivotal trial to commence in H2
				2022, subject to Phase 2a data
Neurodegeneration,				• Additional proof of concept data
Oncology, Vaccines (e.g.				from current research
COVID-19)				collaborations expected in 2021

• Validation of technology

Oncology, Diabetesand publication of pre-clinicalproof-of-concept data

• Currently partnered in China with

Stroke Disability

• Open for partnerships outside

China

© ReNeuron Group plc 2021 All rights reserved

5